Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

1. Pérez de Isla, L.
2. Ray, K.K.
3. Watts, G.F.
4. Santos, R.D.
5. Alonso, R.
6. Muñiz-Grijalvo, O.
7. Diaz-Diaz, J.L.
8. Badimon, L.
9. Catapano, A.L.
10. Mata, P.